With further analysis of CXCL13 expression and CXCL13/CD163 co-expression, the clinical parameters and prognostic factors were discussed, and their immunomodulatory influences in human astrocytoma were evaluated. This evidence concerns the gene CD163 and astrocytoma (excluding glioblastoma).